Dermatology

DDD 2025

AAD 2025

Letter from the Editor

Editor

Prof. Peter van de Kerkhof, Radboudumc, the Netherlands

Conference

AAD 2025

17 April 2025 18:12

What’s new in acne?

Presented By

Dr Julie Claire Harper, Birmingham, AL, USA

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 18:01

Nearly all participants respond to deucravacitinib in lichen planopilaris study

Presented By

Dr Alyssa Stockard , Mayo Clinic, AZ, USA

Trial

Phase 2

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 17:55

Dupilumab in bullous pemphigoid

Presented By

Prof. Frédéric Caux, Avicenne Hospital, University of Paris 13, France

Trial

Phase 3, LIBERTY-BP ADEPT

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 17:52

Breaking the cutaneous lupus loop with deucravacitinib

Presented By

Prof. Victoria Werth, University of Pennsylvania, PA, USA

Trial

Phase 2, PAISLEY CLE

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 17:44

Active psoriatic arthritis: POETYK PsA-2 trial results

Presented By

Prof. Diamant Thaçi, University of Lübeck, Germany

Trial

Phase 3, POETYK PsA-2

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 17:31

Upadacitinib efficacious in palmoplantar pustulosis

Presented By

Prof. Yuling Shi, Tongji University School of Medicine, China

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 17:24

Delgocitinib gets the upper hand in chronic hand eczema

Presented By

Prof. April Armstrong, University of California, Los Angeles, CA, USA

Trial

DELTA

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 17:00

Excellent long-term data for TYK2 inhibitor ESK-001 in psoriasis

Presented By

Dr Andrew Blauvelt, Blauvelt Consulting LLC, MD, USA

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 16:54

ICONIC-LEAD in plaque psoriasis

Presented By

Dr Robert Bissonnette, Innovaderm Research, Canada

Trial

Phase 3, ICONIC-LEAD

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 16:49

A ‘TYK’ above placebo: ICP-488 in plaque psoriasis

Presented By

Dr Xiaoguang Zhang, Second Hospital of Hebei Medical University, China

Trial

Phase 2

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 16:44

TYK2 inhibitor D-2570 safe and effective in psoriasis

Presented By

Dr Ling Zhang, InventisBio Co., China

Trial

Phase 2

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 16:42

Flexing upadacitinib dose adjustment for AD and itch relief

Presented By

Dr Melinda Gooderham, SKiN Health, Canada

Trial

Phase 3, FLEX-UP

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 16:36

ROCKET ignites interest in rocatinlimab

Presented By

Prof. Emma Guttman, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

Phase 3, ROCKET-Horizon

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 16:33

Reduced biopsy rate and improved malignancy rate with high-end imaging tool

Presented By

Dr Jordan Phillipps, Washington University School of Medicine, MO, USA

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 16:24

Cutaneous immune-related AEs may predict toxicities in ICI-treated patients

Presented By

Elle Kim, John Hopkins University, MD, USA

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 16:19

Clinical patterns and outcomes in hypopigmented mycosis fungoides

Presented By

Dr Jong Bin Park, Kosin University, South Korea

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 16:10

Bempikibart shows its potential for hair regrowth in alopecia areata

Presented By

Dr Brett King, Yale Medicine, CT, USA

Trial

Phase 2, SIGNAL-AA

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 16:08

Ivarmacitinib stimulates hair regrowth in severe alopecia areata

Presented By

Prof. Jianzhong Zhang, Peking University People’s Hospital, China

Trial

Phase 3

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 15:51

Baricitinib regrows hair in adolescents with alopecia areata

Presented By

Prof. Thierry Passeron, Nice University Hospital, France

Trial

Phase 3, BRAVE-AA-PEDS

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 15:41

Briquilimab breaks walls in chronic spontaneous urticaria

Presented By

Prof. Martin Metz, Charité Universitätsmedizin, Germany

Trial

Phase 1/2, BEACON

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 15:34

New anti-IL-23p19 inscribes its name on the plaque

Presented By

Dr Furen Zhang, Shandong Academy of Medical Science, China

Trial

Phase 2

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 15:20

AAD 2025 Highlights Podcast 

Presented By

Dr Rachel Giles & Robert van den Heuvel, Medicom

Conference

AAD 2025

20 March 2025 15:39

EADV 2024

Letter from the Editor

Editor

Prof. Peter van de Kerkhof, Radboudumc, the Netherlands

Conference

EADV 2024

6 November 2024 15:34

3-Year results highlight durable effects of IL-13 inhibitor in AD

Presented By

Prof. Diamant Thaçi, University of Lübeck, Germany

Trial

ADjoin

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:59

IL-22RA1 inhibition shows potential in atopic dermatitis

Presented By

Dr Christine Bangert, Medical University Vienna, Austria

Trial

Phase 2

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:56

Lifelong psychosocial burden linked to early-onset atopic dermatitis

Editor

George Washington University School of Medicine, USA

Trial

Scars of Life

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:53

Second-generation selective PDE4 inhibitor shows promise in AD

Presented By

Prof. Eric Simpson, Oregon Health and Science University, USA)

Trial

Phase 2, ADESOS

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:50

Prurigo nodularis: long-term treatment decreases relapse events

Presented By

Prof. Franz Legat, Medical University Graz, Austria

Trial

Phase 3

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:47

JAK1 inhibitor shows promising long-term efficacy in PN

Presented By

Dr Shawn Kwatra, Johns Hopkins University School of Medicine, USA

Trial

Phase 2

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:44

Deucravacitinib treatment in lichen planopilaris

Presented By

Dr Aaron Mangold, Mayo Clinic, USA

Trial

Phase 2

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:41

Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema

Presented By

Prof. Ana Giménez-Arnau, Autonomous University of Barcelona, Spain

Trial

Phase 3, DELTA FORCE

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:33

Atopic hand eczema: similar treatment success for dupilumab and topical delgocitinib

Presented By

Prof. April Armstrong, University of California Los Angeles, USA

Trial

DELTA; LIBERTY-AD-HAFT

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:30

Targeting IL-17A offers a promising treatment perspective in hidradenitis suppurativa

Presented By

Dr Kim Papp, Probity Medical Research, Canada

Trial

Phase 3

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:26

Bimekizumab shows sustained 2-year efficacy in hidradenitis suppurativa

Presented By

Prof. Christos Zouboulis, Dessau Medical Center, Germany

Trial

BE HEARD

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:22

Familial hidradenitis suppurativa tied to metabolic disease

Presented By

Dr Suzan Al-Gburi, University Hospital Cologne, Germany

Trial

EpiCAi; BATMAN

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:19

Imsidolimab potential future therapeutic avenue for generalised pustular psoriasis

Presented By

Prof. Adam Reich, University of Rzeszów, Poland

Trial

Phase 3, GEMINI-1; GEMINI-2

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:04

A new era of care: Artificial intelligence in psoriasis

Presented By

Prof. Alexander Navarini, University Hospital of Basel, Switzerland

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:00

Deuruxolitinib significantly improves hair satisfaction in AA

Presented By

Dr Paradi Mirmirani, Kaiser Permanente Vallejo Medical Center, USA

Trial

THRIVE-AA

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 12:56

Topical pan-JAK inhibitor mitigates inflammatory biomarkers in frontal fibrosing alopecia

Presented By

Prof. Maryanne Senna, Harvard Medical School, USA

Trial

Phase 2

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 12:51

Vitiligo: Prolonged facial re-pigmentation maintained with continued ruxolitinib cream

Presented By

Dr David Rosmarin, Indiana University School of Medicine, USA

Trial

TRuE-V

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 12:39

Anti-KIT antibody: the next frontier in CSU treatment?

Presented By

Prof. Martin Metz, Charité-University Hospital Berlin, Germany

Trial

Phase 2

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 12:33

New targets identified for acute and chronic wound healing

Presented By

Dr Marta Bertolini, (QIMA Monasterium GmbH, Germany

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 12:29

PsoBest registry: Biologics dominate treatment for moderate-to-severe psoriasis

Presented By

Prof. Matthias Augustin, University Medical Center Hamburg-Eppendorf, Germany

Trial

PsoBest registry

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 12:23

Semaglutide improves outcomes for patients with obesity and HS

Presented By

Dr Daniel Lyons, St Vincent’s University Hospital, Ireland

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 12:14

Advanced BCC: histological subtype and time to complete response may predict tumour recurrence

Presented By

Dr Maria Mannino, Catholic University of the Sacred Heart, Italy

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 12:02

EADV 2024 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

EADV 2024

9 October 2024 23:36

IFPA 2024

DDD 2024

Letter from the Editor

Editor

Prof. Peter van de Kerkhof, Radboud University, the Netherlands

Conference

DDD 2024

31 May 2024 14:03

The management of lymphoedema in 2024

Presented By

Dr Kirsten van Duinen, Nij Smellinghe Hospital, the Netherlands

Conference

DDD 2024

Type

Peer-reviewed article

31 May 2024 13:53

Diagnosing skin disorders in patients with skin of colour

Presented By

Dr Deepak Balak, Leiden University Medical Center, the Netherlands

Conference

DDD 2024

Type

Peer-reviewed article

31 May 2024 13:50

What’s new in clinical dermatology?

Presented By

Dr Tamar Nijsten, Erasmus University Medical Centre, the Netherlands

Conference

DDD 2024

Type

Peer-reviewed article

31 May 2024 13:31

Safety and efficacy of a therapeutic HPV vaccine in high-grade anal intraepithelial neoplasia

Presented By

Dr Karien Gosens, Mauritskliniek, the Netherlands

Trial

Phase 1/2, VACCAIN-T

Conference

DDD 2024

Type

Peer-reviewed article

31 May 2024 13:08

Artificial intelligence in dermatology: current applications and future horizons

Presented By

Tobias Sangers, Leiden University Medical Center, the Netherlands

Conference

DDD 2024

Type

Peer-reviewed article

31 May 2024 13:01

Digital dermatology in the Dutch treatment landscape

Presented By

Dr Milan Tjioe, Bravis Hospital, the Netherlands

Conference

DDD 2024

Type

Peer-reviewed article

31 May 2024 12:57

Improving risk classification in cutaneous squamous cell carcinoma

Presented By

Dr Marlies Wakkee, Erasmus MC Rotterdam, the Netherlands

Conference

DDD 2024

Type

Peer-reviewed article

31 May 2024 12:54

Skin cancer in transplant patients: practical challenges

Presented By

Dr Elsemieke Plasmeijer, Leiden University Medical Center, the Netherlands

Conference

DDD 2024

Type

Peer-reviewed article

31 May 2024 12:47

Ins and outs of tumour-infiltrating lymphocytes therapy in metastatic melanoma

Presented By

Dr Tom Seijkens, Netherlands Cancer Institute, the Netherlands

Conference

DDD 2024

31 May 2024 12:40

Understanding bullous pemphigoid: a rare skin condition

Presented By

Prof. Barbara Horváth, University Medical Center Groningen, the Netherlands

Conference

DDD 2024

Type

Peer-reviewed article

31 May 2024 12:24

Advancements in gene therapy for epidermolysis bullosa

Presented By

Dr Peter van den Akker, University Medical Center Groningen, the Netherlands

Conference

DDD 2024

Type

Peer-reviewed article

31 May 2024 12:22

Interview: State-of-the-art dermatology care in the Netherlands: “The future of dermatology is bright”

Expert

Prof. Peter van de Kerkhof, Radboudumc, the Netherlands

7 May 2024 14:48

DDD 2024 Highlights Podcast

Presented By

Robert van den Heuvel, Medicom

Conference

DDD 2024

6 May 2024 10:43

AAD 2024

Letter from the Editor

Presented By

Prof. Peter van de Kerkhof, Radboudumc, the Netherlands

Conference

AAD 2024

22 April 2024 17:00

Children with atopic dermatitis may be smaller and heavier than healthy children

Presented By

Prof. Amy Paller, Northwestern University‘s Feinberg School of Medicine, USA

Trial

PEDISTAD

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 16:54

JAK inhibitors have similar incidence rates of long-term adverse events as traditional immunomodulators

Presented By

Olivia Lamberg, University of Michigan, USA

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 16:52

Baricitinib maintains regrowth of hair, eyebrows, and eyelashes over 3 years

Presented By

Prof. Maryanne Senna, Harvard Medical School, USA

Trial

BRAVE-AA

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 16:43

GUIDE demonstrates: Hit hard and early in psoriasis

Presented By

Prof. Knut Schäkel, University Clinic Heidelberg, Germany

Trial

Phase 3, GUIDE

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 16:36

Hidradenitis suppurativa treatment with secukinumab linked to low immunogenicity

Presented By

Prof. Martina Porter, Beth Israel Deaconess Medical Center, USA

Trial

Phase 3, SUNSHINE; SUNRISE

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 16:33

HS: Targeting IL-1 pathway potential option after anti-TNF failure

Presented By

Prof. Falk Bechara, Ruhr-University Bochum, Germany

Trial

Phase 2

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 16:29

BTK signalling as a novel target in hidradenitis suppurativa treatment

Presented By

Prof. Alexandra Kimball, Harvard Medical School, USA

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 16:20

Topical ruxolitinib shows promise in milder stages of hidradenitis suppurativa

Presented By

Prof. Martina Porter, Beth Israel Deaconess Medical Center, MA, USA

Trial

Phase 2

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 16:16

Robust long-term efficacy of bimekizumab in psoriasis

Presented By

Prof. Mark Lebwohl, Icahn School of Medicine at Mount Sinai, USA

Trial

BE BRIGHT

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 16:09

Benefit and safety of TYK2 inhibitor ESK-001 for psoriasis in phase 2

Presented By

Dr Kim Papp, Probity Medical Research, Canada

Trial

Phase 2, STRIDE

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 16:01

Durable skin clearance by IL-23 blockers due to reduction of resident memory T cells

Presented By

Prof. Andrew Blauvelt, Oregon Medical Research Center, USA

Trial

Phase 2, KNOCKOUT

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 15:41

Amlitelimab leads to a high response 28 weeks after treatment discontinuation

Presented By

Prof. Stephan Weidinger, Christian-Albrechts-University Kiel, Germany

Trial

Phase 2, STREAM-AD

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 15:35

Delgocitinib cream: A promising treatment option for chronic hand eczema

Presented By

Prof. Melinda Gooderham, Queens University, Canada

Trial

Phase 3, DELTA 3

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 15:31

Upadacitinib: A novel treatment option for vitiligo

Presented By

Prof. Thierry Passeron, Nice University Hospital, France

Trial

Phase 2

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 15:21

JAK1 inhibitor meets primary endpoint in prurigo nodularis

Presented By

Prof. Martin Metz, Charité University Hospital, Germany

Trial

Phase 2

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 15:17

Botanical drug solution leads to sustained hair regrowth in paediatric alopecia

Presented By

Prof. Bianca Piraccini, University of Bologna, Italy

Trial

RAAINBOW

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 15:14

SGLT2 inhibition: A possible mode-of-action for inflammatory skin diseases?

Presented By

Allison Holt, UMass Chan Medical School, USA

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 15:06

Promising first results of novel topical treatment for congenital ichthyosis

Presented By

Dr Christopher Bunick, Yale School of Medicine, USA

Trial

Phase 3, ASCEND

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 15:02

Ritlecitinib also effective in patients with total hair loss

Presented By

Dr Melissa Piliang, Cleveland Clinic, USA

Trial

Phase 3, ALLEGRO

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 14:57

Meet the Trialist: Dr Andrew Blauvelt on the KNOCKOUT Trial

Expert

Dr Andrew Blauvelt

Trial

Phase 2, KNOCKOUT

Conference

AAD 2024

22 April 2024 12:12

AAD 2024 Highlights Podcast

Presented By

Robert van den Heuvel, Medicom

Conference

AAD 2024

24 March 2024 15:02

EADV 2023

Letter from the Editor

Editor

Prof. Peter van de Kerkhof

Conference

EADV 2023

28 November 2023 13:52

Tapinarof on course to become a new topical treatment in AD

Presented By

Dr Jonathan Silverberg, George Washington University, USA

Trial

Phase 3, ADORING

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 13:43

Upadacitinib provides sustained skin clearance in adolescents and adults with AD

Presented By

Dr Jonathan Silverberg, George Washington University, USA

Trial

Phase 3, Measure Up; AD UP

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 13:39

Sustained deep clinical and itch responses with novel IL-13 inhibitor

Presented By

Prof. Eric Simpson, Oregon Health & Science University, USA

Trial

Phase 3, ADvocate; ADvantage

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 13:13

IL-13 inhibitor shows potential in atopic dermatitis

Presented By

Prof. Eric Simpson, Oregon Health and Science University, USA

Trial

Phase 2, TREK-AD

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 13:08

Encouraging results for amlitelimab in atopic dermatitis

Presented By

Prof. Stephan Weidinger, University Hospital Schleswig-Holstein, Germany

Trial

Phase 2, STREAM-AD

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 13:03

Chronic hand eczema: patients share similar molecular signatures regardless of AD status

Presented By

Dr Jonathan Bar, Icahn School of Medicine at Mount Sinai, USA

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:58

Severe hand eczema: dupilumab could be a future treatment

Presented By

Dr Laura Loman, University Medical Center Groningen, the Netherlands

Trial

Phase 2

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:55

Dual IL-17 blockade yields efficacy on joints and skin

Presented By

Prof. Diamant Thaçi, University of Lübeck, Germany

Trial

Phase 3, BE OPTIMAL; BE COMPLETE

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:27

High-dose subcutaneous spesolimab prevents GPP flares up to week 48

Presented By

Prof. Matthias Augustin, University Medical Center Hamburg-Eppendorf, Germany

Trial

Phase 2, Effisayil 2

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:23

Drug survival of guselkumab and risankizumab seems superior to other biologics

Presented By

Dr Zenas Yiu, University of Manchester, UK

Trial

BADBIR

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:04

IL-23 blockers may lower the risk of developing inflammatory and psoriatic arthritis

Presented By

Prof. Bruce Strober, Yale University School of Medicine, USA

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:01

First-in-class oral IL-23 inhibitor safe and effective for moderate-to-severe plaque psoriasis

Presented By

Dr Robert Bissonnette, Innovaderm Research, Canada

Trial

Phase 2, FRONTIER 1

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 11:57

Skin tape stripping allows a novel precision medicine approach in HS

Presented By

Dr Kristina Navrazhina, Icahn School of Medicine at Mount Sinai, USA

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 11:51

Nanobodies: A novel way to treat HS

Presented By

Prof. Brian Kirby, St. Vincent´s University Hospital, Ireland

Trial

Phase 2, MIRA

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 11:48

Anti-IL17 blockade leads to maintained pain reduction in patients with HS

Presented By

Dr John Ingram, Cardiff University, UK

Trial

Phase 3, SUNSHINE; SUNRISE

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 11:44

JAK1 inhibition: a promising forthcoming treatment option in vitiligo

Presented By

Prof. Khaled Ezzedine, University Paris-Est Créteil, France

Trial

Phase 2

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 11:17

Vitiligo: Continuation of topical ruxolitinib successful in many initial non-responders

Presented By

Dr Albert Wolkerstorfer, Amsterdam University Medical Centers, the Netherlands

Trial

Phase 3, TRuE-V1; TRuE-V1

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 11:10

JAK3/TEC inhibition achieves clinically meaningful responses in AA

Presented By

Dr Athanasios Tsianakas, Fachklinik Bad Bentheim, Germany

Trial

Phase 3, ALLEGRO-LT

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 10:31

Alopecia areata: remarkable regrowth rates with deuruxolitinib

Presented By

Prof. Brett King, Yale University School of Medicine, USA

Trial

Phase 3, THRIVE-AA

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 10:28

Botanical drug solution improves hair regrowth in children and adolescents with AA

Presented By

Prof. Ulrike Blume-Peytavi, Charité – Berlin University Medicine, Germany

Trial

RAAINBOW

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 10:23

Nemolizumab shows high success rates in prurigo nodularis

Presented By

Prof. Sonja Ständer, Münster University Hospital, Germany

Trial

Phase 3, OLYMPIA 1

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 10:19

Remibrutinib reduces itch, sleep problems, and activity impairment in patients with CSU

Presented By

Dr Ana Giménez-Arnau, Autonomous University and Pompeu Fabra University, Spain

Trial

Phase 2

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 10:13

Innovative wound gel reduces frequency of painful dressing changes in epidermolysis bullosa

Presented By

Prof. Dimitra Kiritsi, University of Freiburg, Germany

Trial

Phase 3, EASE

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 10:08

Women with psoriasis face increased adverse effects with systemic therapy

Presented By

Dr Fabio Verardi, University Hospital Zurich, Switzerland

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 09:50

Improved AI tool shows high sensitivity rates in skin cancer detection

Presented By

Dr Kashini Andrew, University Hospitals Birmingham NHS Foundation Trust, UK

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 09:46

Dermoscopy training combined with AI significantly improves skin cancer detection

Presented By

Dr Christian Dorado Cortez, University Hospital of Saint-Etienne, France

Conference

EADV 2024

Type

Peer-reviewed article

28 November 2023 09:43

EADV 2023 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

EADV 2023

30 October 2023 01:34

Alopecia areata: Ritlecitinib generates substantial re-growth of scalp hair

Presented By

Dr Athanasios Tsianakas, Fachklinik Bad Bentheim, Germany

Trial

ALLEGRO-LT

Conference

EADV 2023

18 October 2023 12:11

Promising results in AD treatment with an OX40 ligand inhibitor

Presented By

Prof. Stephan Weidinger, University Hospital Schleswig-Holstein, Germany

Trial

Phase 2, STREAM-AD

Conference

EADV 2023

18 October 2023 12:09

Differential effect of biologics for psoriasis on the risk of developing arthritis

Presented By

Prof. Bruce Strober, Yale University School of Medicine, CT, USA

Conference

EADV 2023

18 October 2023 12:05

Innovative wound gel significantly reduces daily dressing changes in epidermolysis bullosa

Presented By

Prof. Dimitra Kiritsi, University of Freiburg, Germany

Trial

EASE

Conference

EADV 2023

18 October 2023 12:03

Generalised pustular psoriasis: IL-36 inhibits new flares up to week 48

Presented By

Prof. Matthias Augustin, University Medical Center Hamburg-Eppendorf, Germany

Trial

Effisayil 2

Conference

EADV 2023

18 October 2023 12:01

Patience is rewarded in initial non-responders to topical ruxolitinib with vitiligo

Presented By

Dr Albert Wolkerstorfer, Amsterdam University Medical Center, Netherlands

Trial

Phase 3, TRuE-V1; TRuE-V2

Conference

EADV 2023

17 October 2023 11:23

Women with psoriasis face increased adverse effects with systemic therapy

Presented By

Dr Fabio Verardi, University Hospital Zurich, Switzerland

Trial

Swiss Psoriasis Registry (SDNTT)

Conference

EADV 2023

17 October 2023 11:21

Dupilumab – a future option for severe hand eczema?

Presented By

Dr Laura Loman, University Medical Centre Groningen, Netherlands

Trial

Phase 2

Conference

EADV 2023

17 October 2023 11:20

Vitiligo: Oral JAK1 inhibitor induces increasing repigmentation over time

Presented By

Prof. Khaled Ezzedine, University Paris-Est Créteil, France

Conference

EADV 2023

17 October 2023 11:18

IL-23p19 inhibitors have a superior drug survival compared with other biologics

Presented By

Dr Zenas Yiu, University of Manchester, UK

Trial

BADBIR Registry

Conference

EADV 2023

17 October 2023 11:17

Skin tape stripping: Can it pave the way for early diagnosis in HS?

Presented By

Dr Kristina Navrazhina, Icahn School of Medicine at Mount Sinai, NY, USA

Conference

EADV 2023

17 October 2023 11:15

Topical tapinarof – a rising star in atopic dermatitis

Presented By

Dr Jonathan Silverberg, The George Washington University School of Medicine, USA

Trial

Phase 3, ADORING 1; ADORING 2

Conference

EADV 2023

16 October 2023 11:46

Botanical drug solution improves hair regrowth in children and adolescents with AA

Presented By

Prof. Ulrike Blume-Peytavi, Charité – Universitätsmedizin Berlin, Germany

Trial

RAAINBOW

Conference

EADV 2023

16 October 2023 11:43

Anti-IL17 blockade leads to maintained pain reduction in patients with HS

Presented By

Dr John Ingram, Cardiff University, UK

Trial

Phase 3, SUNSHINE; SUNRISE

Conference

EADV 2023

16 October 2023 11:41

Nemolizumab shows high success rates in prurigo nodularis

Presented By

Prof. Sonja Ständer, Münster University Hospital, Germany

Trial

Phase 3, OLYMPIA 1

Conference

EADV 2023

16 October 2023 11:40

JAK inhibitor provides sustained skin clearance in adolescents and adults with AD

Presented By

Dr Jonathan Silverberg, The George Washington University School of Medicine, USA

Trial

Phase 3, Measure Up 1; Measure Up 2; AD UP

Conference

EADV 2023

16 October 2023 11:37

Nanobody sonelokimab shows efficacy in hidradenitis suppurativa

Presented By

Prof. Bryan Kirby, St. Vincent’s University Hospital, Ireland

Trial

Phase 2, MIRA

Conference

EADV 2023

16 October 2023 11:36

WCD 2023

Letter from the Editor

Presented By

Peter van de Kerkhof, Radboudumc, the Netherlands

Conference

WCD 2023

31 August 2023 18:18

Rocatinlimab delivers efficacy and safety in atopic dermatitis

Presented By

Prof. Emma Guttman-Yassky, Icahn School of Medicine at Mount Sinai, NY, USA

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 18:08

Head-to-head: paraffin- versus ceramide-based moisturiser for paediatric AD

Presented By

Prof. Sachin Gupta, All India Institute of Medical Sciences, India

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 18:06

JAK inhibitors for AD in the real world

Presented By

Dr Yik Weng, National Skin Centre, Singapore

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 18:02

Novel JAK1 inhibitor for patients with atopic dermatitis

Presented By

Jianzhong Zhang, Peking University People’s Hospital, China

Trial

Phase 3, QUARTZ3

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 18:00

Can lebrikizumab maintain response rates in atopic dermatitis?

Presented By

Prof. Emma Guttman-Yassky, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

Phase 3, ADvocate 1 and ADvocate 2

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 17:58

Most patients with AD on dupilumab stick with this drug long-term

Presented By

Dr Elena Pezzolo, San Bortolo Hospital, Italy

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 17:56

Botulinum toxin A might provide efficacious treatment option for nail psoriasis

Presented By

Dr Premjit Juntongjin, Thammasat University, Thailand

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 17:53

POETYK PSO-1 and 2: Long-term efficacy results of deucravacitinib in plaque psoriasis

Presented By

Prof. Mark Lebwohl, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

POETYK PSO-LTE

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 17:52

Encouraging results for first oral IL-23 receptor antagonist in plaque psoriasis

Presented By

Dr Robert Bissonnette, Innovaderm Research, Canada

Trial

Phase 2, FRONTIER 1

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 15:35

Subcutaneous spesolimab for GPP flare prevention

Presented By

Prof. Bruce Strober, Yale University School of Medicine, CT, USA

Trial

Effisayil 2

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 15:32

Knocking out psoriasis with high-dose risankizumab?

Presented By

Dr Andrew Blauvelt, Oregon Medical Research Center, OR, USA

Trial

Phase 2, KNOCKOUT

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 15:30

Deucravacitinib versus other systemic therapies in Asian patients with psoriasis

Presented By

Prof. Tsen-Fang Tsai, (National Taiwan University Hospital, Taiwan

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 15:26

Patients with AA report high long-term regrowth rates with baricitinib

Presented By

Dr Maryanne Senna, Harvard Medical School, MA, USA

Trial

BRAVE-AA1 and BRAVE-AA2

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 15:22

Can ritlecitinib deliver long-term efficacy in alopecia areata?

Presented By

Prof. Melissa Piliang, Cleveland Clinic, OH, USA

Trial

Phase 3, ALLEGRO

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 15:18

TikTok videos on hair disorders lack reliability

Presented By

Dr Betty Nguyen, University of Miami, FL, USA

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 15:14

Spesolimab appears successful in hidradenitis suppurativa

Presented By

Prof. Afsaneh Alavi, Mayo Clinic, MN, USA

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 15:12

Promising results for paroxetine in rosacea

Presented By

Dr Yingxue Huang, Central South University, China

Trial

PRRERCT

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 15:10

Novel PPARγ modulator reduces acne manifestations

Presented By

Prof. Mauro Picardo, International Medical University, Italy

Trial

Phase 3, GEDACNE

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 15:07

Microencapsulated benzoyl peroxide shifts skin microbiome in rosacea

Presented By

Prof. Raja Sivamani, Pacific Skin Institute, CA, USA

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 15:04

OLYMPIA 2: Positive results for nemolizumab in prurigo nodularis

Presented By

Prof. Sonja Ständer, University Hospital Münster, Germany

Trial

Phase 3, OLYMPIA 2

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 14:59

PRFM or PRP therapy for trophic ulcers due to leprosy?

Presented By

Prof. Amrita Sil, Rampurhat Government Medical College & Hospital, India

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 13:19

Large teledermatology project in a remote island in Eastern Indonesia

Presented By

Dr Marlous Grijsen, University of Oxford, UK

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 12:56

Can AI-driven teledermatology increase access to healthcare in rural African settings?

Presented By

Mr Philippe Gottfrois, Basel University, Switzerland

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 12:54

Oleogel-S10 shows long-term efficacy and safety in dystrophic epidermolysis bullosa

Presented By

Prof. Dedee Murrell, University of New South Wales, Australia

Trial

Phase 3, EASE

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 11:50

Picosecond alexandrite laser safe and effective in benign pigmentary disorders

Presented By

Dr Kentaro Oku, Hills Grace Clinic, Japan

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 11:46

Gentamicin improves symptoms in paediatric Nagashima-type palmoplantar keratosis

Presented By

Dr Shan Wang, National Center for Children’s Health, China

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 11:41

WCD 2023 Highlights Podcast

Presented By

Dr Rachel Giles

Conference

WCD 2023

30 July 2023 22:40

AAD 2023

Biologics in psoriasis: can they prevent joint involvement?

Presented By

Ms Kathleen Miao, Keck School of Medicine of USC, CA, USA

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 12:46

JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata

Presented By

Dr Maryanne Senna, Lahey Hospital and Medical Center, MA, USA

Trial

Phase 3, THRIVE-AA1

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 12:41

Biomarkers predicting response of different CSU treatments in children

Presented By

Mr Alex Nguyen, McGill University, Canada

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 12:35

Izokibep shows remarkably high grades of clinical response in HS

Presented By

Dr Kim Papp, Probity Medical Research, Canada

Trial

Phase 3

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 12:31

Bimekizumab could be the new up-and-comer for HS treatment

Presented By

Prof. Alexa Kimball, Harvard Medical School, MA, USA

Trial

Phase 3, BE HEARD I and BE HEARD II

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 12:26

Switching to risankizumab successful in IL-17 inhibitor non-responders

Presented By

Prof. Richard Warren, University of Manchester, UK

Trial

Phase 3, aIMM study

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 11:56

Novel, selective TYK2 inhibitor shows promise for psoriasis

Presented By

Prof. April Armstrong, Keck School of Medicine of University of California, LA, USA

Trial

Phase 2

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 11:51

As-needed ruxolitinib shows successful long-term symptom control in AD

Presented By

Dr Andrew Blauvelt, Oregon Medical Research Center, OR, USA

Trial

Phase 3, TRuE-AD1 and TRuE-AD2

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 11:43

Dupilumab: a viable option for atopic hand and foot eczema

Presented By

Prof. Eric Simpson, Oregon Health & Science University, OR, USA

Trial

Phase 3, LIBERTY-AD-HAFT

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 11:33

Topical roflumilast beneficial in atopic dermatitis

Presented By

Prof. Lawrence Eichenfield, University of California San Diego, CA, USA

Trial

Phase 3, INTEGUMENT-1 and INTEGUMENT-2

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 11:27

IL-22 receptor blocker reduces itch and skin lesions in AD

Presented By

Prof. Diamant Thaçi, University of Lübeck, Germany

Trial

Phase 2

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 11:17

Delgocitinib shows promise as topical therapy for chronic hand eczema

Presented By

Dr Robert Bissonnette, Innovaderm Research, Canada

Trial

Phase 3, DELTA 1

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 10:58

Vitiligo patients maintain re-pigmentation after ruxolitinib cream withdrawal

Presented By

Prof. John Harris, UMass Chan Medical School, MA, USA

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 10:51

Nemolizumab decreases lesions and itch in prurigo nodularis

Presented By

Prof. Shawn Kwatra , Johns Hopkins University School of Medicine, MD, USA

Trial

Phase 3, OLYMPIA 2

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 10:40

Lichen planus: a future indication for baricitinib?

Presented By

Ms Angelina Hwang , Mayo Clinic College of Medicine, AZ, USA

Trial

Phase 2

Conference

AAD

Type

Peer-reviewed article

15 May 2023 09:58

Letter from the Editor

Editor

Prof. Peter van de Kerkhof, Radboud University, the Netherlands

Conference

AAD 2023

11 May 2023 16:48

AAD 2023 Highlights Podcast

Presented By

Robert van den Heuvel, Medicom

Conference

AAD 2023

4 April 2023 23:46

DDD 2023

Letter from the Editor

Editor

Prof. Peter van de Kerkhof, Radboud University, the Netherlands

Conference

DDD 2023

11 May 2023 14:17

Eligibility and selection of JAK inhibitors for constitutional eczema

Presented By

Dr Dirk Jan Hijnen, Erasmus MC, the Netherlands

Conference

DDD 2023

Type

Peer-reviewed article

10 May 2023 13:57

The rise of JAK inhibitors for alopecia areata

Presented By

Dr Brett King, Yale University, CT, USA

Conference

DDD 2023

Type

Peer-reviewed article

10 May 2023 13:47

Obesity and the skin: state of affairs

Presented By

Dr Mariëtte Boon , Leiden University Medical Center, the Netherlands

Conference

DDD 2023

Type

Peer-reviewed article

10 May 2023 13:30

The role of surgeons in stage I–II melanoma

Presented By

Dr Dirk Grünhagen, Erasmus MC, the Netherlands

Conference

DDD 2023

Type

Peer-reviewed article

10 May 2023 13:26

Skin diseases and nutrition

Presented By

Prof. Reinhart Speeckaert, UZ Gent, Belgium

Conference

DDD 2023

Type

Peer-reviewed article

10 May 2023 13:21

Melanoma: Surveillance and follow-up

Presented By

Dr Remco van Doorn, Leiden University Medical Center, the Netherlands

Conference

DDD 2023

Type

Peer-reviewed article

10 May 2023 13:19

When to screen for anal intraepithelial neoplasia?

Presented By

Prof. Henry de Vries, Amsterdam UMC, the Netherlands

Conference

DDD 2023

Type

Peer-reviewed article

10 May 2023 13:12

The importance of anti-microbial proteins in the skin

Presented By

Dr Hanna Niehues, Radboud University Medical Center, the Netherlands

Conference

DDD 2023

Type

Peer-reviewed article

10 May 2023 13:08

Scabies: Therapy failure and tips for the clinic

Presented By

Dr Robert Vodegel, Medical Center Leeuwarden, the Netherlands

Conference

DDD 2023

Type

Peer-reviewed article

10 May 2023 13:03

Life-threatening skin infections

Presented By

Dr Sandra Arend , Leiden UMC, the Netherlands

Conference

DDD 2023

Type

Peer-reviewed article

10 May 2023 12:58

OCT non-inferior to biopsy in basal cell carcinoma

Presented By

Dr Tom Wolswijk , Maastricht UMC, the Netherlands

Conference

DDD 2023

Type

Peer-reviewed article

10 May 2023 12:42

DDD 2023 Highlights Podcast

Presented By

Robert van den Heuvel, Medicom

Conference

DDD 2023

27 March 2023 06:34

EADV 2022

Letter from the Editor

Editor

Prof. Peter CM van de Kerkhof, Radboud University Nijmegen Medical Centre, the Netherlands

Conference

EADV2022

5 November 2022 11:24

High rate of non- or partial responders jeopardises therapeutic success in HS

Presented By

Dr Hayley Wallinger, Adelphi Real World, UK

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 11:15

Genital psoriasis: high prevalence, often underdiagnosed

Presented By

Dr Toni Klein, University Medical Center Hamburg-Eppendorf, Germany

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 11:12

Decreased overall survival in melanoma patients with low vitamin D

Presented By

Dr Inés Gracia-Darder, Son Espases University Hospital, Spain

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 11:09

High potential for secukinumab as next biologic treatment for HS

Presented By

Prof. Alexandra Kimball, Harvard Medical School, MA, USA

Trial

Phase 3, SUNSHINE; SUNRISE

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 11:06

Hidradenitis suppurativa: TYK2/JAK1 inhibitor shows promise

Presented By

Prof. Alexandra Kimball, Harvard Medical School, MA, USA

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 11:03

Dupilumab leads to clinically relevant improvements in signs and symptoms of prurigo nodularis

Presented By

Prof. Gil Yosipovitch, University of Miami, FL, USA

Trial

Phase 2, LIBERTY-PN PRIME

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 10:59

Nalbuphine: aspiring to become another treatment for prurigo nodularis?

Presented By

Prof. Sonja Ständer, University Medical Centre of Münster, Germany

Trial

Phase 3, PRISM

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 10:57

Notalgia paresthetica: may κ-opioid receptor agonists be a long-awaited effective therapy?

Presented By

Prof. Mark Lebwohl, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

Phase 2, KOMFORT

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 10:55

Enhancing re-pigmentation rates with topical ruxolitinib in all body areas

Presented By

Prof. Thierry Passeron, University Côte d’Azur, France

Trial

Phase 3, TRuE-V1; TRuE-V2

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 10:50

Markedly lower skin cancer risk in vitiligo patients

Presented By

Dr John Ferguson, St John’s Institute of Dermatology, UK

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 10:47

Myths regarding “health benefit” of suntan prevail in majority of population

Presented By

Prof. Thierry Passeron, Université Côte d’Azur, France

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 10:43

Fern extract reverses severe actinic keratosis lesions

Presented By

Dr Stefania Guida, Sapienza University of Rome, Italy

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 10:41

Novel oral psoriasis drug maintains efficacy over 2 years

Presented By

Prof. Mark Lebwohl, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

Phase 3, POETYK-PSO-1

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 10:36

A3 adenosine receptor agonist showed modest efficacy but excellent tolerability

Presented By

Dr Kim A. Papp, Probity Medical Research, Canada

Trial

Phase 3, COMFORT

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 10:32

Selective IL-23 inhibitor achieves long-term disease control in many patients with active PsA

Presented By

Dr Kim Papp, Probity Medical Research, Canada

Trial

KEEPsAKE 1; KEEPsAKE 2

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 10:28

AI machine learning algorithm useful in early detection of PsA

Presented By

Dr Jonathan Shapiro, Maccabi Healthcare Services, Israel

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 10:24

Long-term improvement in alopecia areata with ritlecitinib therapy

Presented By

Dr Athanasios Tsianakas, Fachklinik Bad Bentheim, Germany

Trial

Phase 3, ALLEGRO-LT

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 09:30

Topical gel plus finasteride beneficial for patients with androgenetic alopecia

Presented By

Dr Michela Starace, University of Bologna, Italy

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 09:20

Deuruxolitinib achieves hair regrowth, even in patients with severe alopecia areata

Presented By

Prof. Brett King, Yale University School of Medicine, CT, USA

Trial

Phase 3, THRIVE-AA1

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 09:18

Baricitinib possible therapeutic option for children with AD

Presented By

Dr Antonio Torrelo Fernández, Hospital Infantil Universitario Niño Jesús, Spain

Trial

Phase 3, BREEZE-AD-PEDS

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 09:15

Amlitelimab therapy leads to sustained decrease of IL-22 in AD patients

Presented By

Dr Stephan Weidinger, University Hospital Schleswig-Holstein, Germany

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 09:10

IL-13 inhibition with lebrikizumab shows high maintenance rates in AD

Presented By

Prof. Andrew Blauvelt, Oregon Medical Research Center, OR, USA

Trial

Phase 3, ADvocate

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 09:05

Does 8 weeks of emollients use prevent AD in high-risk infants?

Presented By

Prof. Alan Irvine, Trinity College Dublin, Ireland

Trial

STOP AD

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 09:02

Roflumilast foam led to high response rates in seborrheic dermatitis

Presented By

Prof. Andrew Blauvelt, Oregon Medical Research Center, OR, USA

Trial

Phase 3, STRATUM

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 09:00

EADV 2022 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

EADV 2022

27 September 2022 11:49

SPIN 2022

Letter from the Editor

Editor

Prof. Peter C.M. van de Kerkhof, Radboud University Medical Center, the Netherlands

Conference

SPIN 2022

26 August 2022 11:00

Therapies for atopic dermatitis: still moving forward

Presented By

Prof. Christian Vestergaard, Aarhus University Hospital, Denmark

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:58

Children with AD: high risk of bacterial infections in carriers of a filaggrin gene variant

Presented By

Prof. Alina Suru , Carol Davila University of Medicine and Pharmacy, Romania

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:53

Men on biologics report fewer adverse events than women

Presented By

Ms Jette van Lint , Pharmacovigilance Centre Lareb, the Netherlands

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:51

Conceptual framework of adverse drug reactions may improve treatment of patients with IMIDs

Presented By

Ms Jette van Lint , Pharmacovigilance Centre Lareb, the Netherlands

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:49

No adverse pregnancy outcomes in patients exposed to baricitinib

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:47

Systemic treatment for psoriasis: what is on the horizon?

Presented By

Prof. Diamant Thaci , University of Lübeck, Germany

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:45

Topical therapy in psoriasis: an important partner in combination therapy

Presented By

Prof. Peter van de Kerkhof, Radboud University Medical Centre, the Netherlands

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:40

GPP flares: pronounced undertreatment is common

Presented By

Dr Wendell Valdecantos , Boehringer Ingelheim Pharmaceuticals, CT, USA

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:38

All patients with GPP benefit from IL-36 inhibitor therapy

Trial

Phase 2, Effisayil 1

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:37

IL-17A/F inhibitor bimekizumab shows higher response and maintenance rates compared with secukinumab

Trial

Phase 3, BE RADIANT

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:35

Greater PASI reductions lead to less impairment in social and sexual life

Trial

Phase 3, VOYAGE 1, VOYAGE 2

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:32

Paediatric psoriasis: ixekizumab beneficial in difficult-to-treat areas

Presented By

Dr Marieke Seyger , Radboud University Medical Centre, the Netherlands

Trial

Phase 3, IXORA-PEDS

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:30

Psoriasis patients see great benefit in achieving complete skin clearance

Presented By

Prof. Matthias Augustin , University Medical Centre Hamburg, Germany

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:25

Predilection sites for skin signs of vitiligo disease activity determined

Presented By

Dr Liesbeth Delbaere , Ghent University Hospital, Belgium

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:24

Vitiligo-childhood onset commonly under 10 years

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:21

IHS4 better suited as an outcome measure in HS trials?

Presented By

Prof. Thrasyvoulos Tzellos, Nordland Hospital Trust, Norway

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:18

New treatments for HS: IL-17 inhibitors next in practice?

Presented By

Dr Axel Villani, University of Lyon, France & Prof. Thrasyvoulos Tzellos, Nordland Hospital Trust, Norway

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:05

Alopecia areata: light at the end of the tunnel

Presented By

Prof. Maryanne Senna , Harvard Medical School, MA, USA

Trial

Phase 3, BRAVE-AA1, BRAVE-AA2

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:01

Alopecia areata pathogenesis: known genetic background, unknown environmental triggers

Presented By

Prof. Rodney Sinclair , University of Melbourne, Australia

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 09:56

Psoriasis treatment: no elevation of MACE and VTE on deucravacitinib

Presented By

Prof. Mark Lebwohl , Icahn School of Medicine at Mount Sinai, NY, USA

Trial

Phase 3, POETYK PSO-1, POETYK PSO-2

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 09:50

Comorbid anxiety and depression may benefit from psoriasis treatment with certolizumab

Presented By

Prof. April Armstrong, Keck School of Medicine of USC, CA, USA

Trial

Phase 3, CIMPASI-1, CIMPASI-2

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 09:47

Dose tapering in psoriasis is associated with a low relapse rate

Presented By

Dr Juan Raul Castro Ayarza , Medicarte, Colombia

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 09:43

SPIN 2022 Highlights Podcast

Presented By

Robert van den Heuvel, Medicom

Conference

SPIN 2022

19 July 2022 00:24

AAD 2022

Inpatient dermatologic therapy is linked to lower mortality and readmission rates

Presented By

Dr Pranav Puri

Conference

AAD 2022

Type

Peer-reviewed article

18 May 2022 12:31

AD treatment during the pandemic: dupilumab does not raise COVID-19 infection risk

Presented By

Dr Brian Rankin, University of Calgary, Canada

Trial

Cohort study

Conference

AAD 2022

Type

Peer-reviewed article

18 May 2022 12:27

Letter from the Editor

Editor

Prof. Peter C.M. van de Kerkhof, Radboud University Medical Center, the Netherlands

Conference

AAD 2022

17 May 2022 12:36

Upadacitinib: Fast and more pronounced skin improvement in AD patients

Presented By

Prof. Jonathan Silverberg, George Washington University School of Medicine, USA

Trial

Phase 3, Heads Up

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 12:35

Dermatology diseases need the highest doses of biologics

Presented By

Dr Charlotte Greif, Beth Israel Deaconess Medical Center, USA

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 12:24

JAK inhibitors in AD: Setting the efficacy bar even higher

Presented By

Prof. Eric Simpson, Oregon Health & Science University, USA

Trial

Measure Up 1; JADE Mono-1; JADE Compare; Heads Up

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 12:21

Lebrikizumab treatment leads to encouraging outcomes in multiple traits of AD

Presented By

Prof. Jonathan Silverberg, George Washington University School of Medicine, USA

Trial

Phase 3, ADvocate 1; ADvocate 2

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 12:18

Novel IL-4/IL-13 blocker shows high efficacy with only modest conjunctivitis signal

Presented By

Prof. Andrew Blauvelt, Oregon Medical Research Center, USA

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 12:15

New insights into psoriasis comorbidity

Presented By

Prof. Joel Gelfand, University of Pennsylvania, USA

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 12:12

Long-term psoriasis treatment with bimekizumab results in maintained efficacy

Presented By

Prof. Kenneth Gordon, Medical College of Wisconsin, USA

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 12:09

Novel developments in topical psoriasis therapy

Presented By

Prof. April Armstrong, University of Southern California Keck School of Medicine, USA

Trial

Phase 3, PSOARING; PSO-LONG

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 12:06

Add-on apremilast may improve recalcitrant dermatomyositis

Presented By

Prof. Carole Bitar, Tulane University School of Medicine, USA

Trial

Phase 2

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 12:03

Could dupilumab put an end to the therapeutic draught in prurigo nodularis?

Presented By

Prof. Gil Yosipovitch, University of Miami, USA

Trial

Phase 3, LIBERTY-PN PRIME 2

Conference

AAD 2022

17 May 2022 11:59

Fungal skin infections in children: A diagnosis to keep in mind

Presented By

Prof. A. Yasmine Kirkorian, George Washington University School of Medicine, USA

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 11:54

Innovative gel speeds up clearance of molluscum contagiosum lesions

Presented By

Prof. John Browning, University of Texas, USA

Trial

Phase 3, B-SIMPLE4

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 11:51

JAK inhibition offers promising treatment prospects for uncommon dermatoses

Presented By

Prof. Matthew Vesely, Yale School of Medicine, USA

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 11:48

JAK inhibitors may offer a new horizon in the treatment of sarcoidosis

Presented By

Prof. William Damsky, Yale School of Medicine, USA

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 11:12

Light at the end of the tunnel for vitiligo therapy

Presented By

Dr David Rosmarin, Tufts Medical Center, USA

Trial

Phase 3, TRuE-V1; TRuE-V2

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 11:05

JAK inhibitors: A risk assessment

Presented By

Prof. Brett King, Yale School of Medicine, USA

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 10:59

Monitoring is key during JAK inhibitor therapy

Presented By

Prof. Jonathan Silverberg

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 10:47

Intestinal microbe-preparation: Modest activity but safe for mild psoriasis

Presented By

Dr Douglas Maslin

Trial

Phase 2

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 10:40

Alopecia areata: 1-year baricitinib treatment increases success

Presented By

Prof. Brett King, Yale School of Medicine, USA

Trial

Phase 3, BRAVE-AA1; BRAVE-AA2

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 10:35

New anticholinergic preparation is effective and tolerable in hyperhidrosis

Presented By

Prof. David Pariser, Eastern Virginia Medical School, USA

Trial

Phase 3, Cardigan I and II

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 10:23

AAD 2022 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

AAD 2022

14 April 2022 11:02

PFGC 2021

Letter from the Editor

Editor

Prof. Peter C.M. van de Kerkhof, Radboud University Medical Center, the Netherlands

Conference

PFGC 2021

3 February 2022 16:11

Potential biomarker discovered for treatment response to ustekinumab

Presented By

Mr Shane Solanky, King’s College London, UK

Conference

PFGC 2021

Type

Peer-reviewed article

3 February 2022 15:46

TNF inhibitor for immune-mediated inflammatory disease doubles the risk of paradoxical psoriasis

Presented By

Dr Nikolai Loft, Copenhagen University Hospital, Denmark

Conference

PFGC 2021

Type

Peer-reviewed article

3 February 2022 15:08

Secukinumab also tolerable in paediatric psoriasis patients

Presented By

Prof. Michael Sticherling, University Erlangen–Nürnberg, Germany

Conference

PFGC 2021

Type

Peer-reviewed article

3 February 2022 11:22

High treatment success with ixekizumab in patients with psoriasis and diabetes

Presented By

Dr Alexander Egeberg, Copenhagen University Hospital Gentofte, Denmark

Trial

Phase 3, UNCOVER

Conference

PFGC 2021

Type

Peer-reviewed article

3 February 2022 11:15

The Yin and Yang of opposing vectors: an explanation for side effects of biologics

Presented By

Prof. Curdin Conrad, Lausanne University Hospital, Switzerland

Conference

PFGC 2021

Type

Peer-reviewed article

3 February 2022 11:07

Explaining arthropathy development through IL-4 and IL-13 blockade

Presented By

Dr Charlie Bridgewood, University of Leeds, UK

Conference

PFGC 2021

Type

Peer-reviewed article

3 February 2022 10:51

DLQI scores underestimated during lockdowns?

Presented By

Dr Ali Alsharqi, St. Vincent’s University Hospital, Ireland

Conference

PFGC 2021

Type

Peer-reviewed article

3 February 2022 10:34

TNF blockers likely beneficial for psoriatic patients with COVID-19

Presented By

Prof. Catherine Smith, King’s College London, UK

Trial

PsoProtect

Conference

PFG 2021

Type

Peer-reviewed article

2 February 2022 15:42

Patients on immunomodulators need 2 COVID-19 vaccinations before seroconversion

Presented By

Dr Ali Al-Janabi, University of Manchester, UK

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 15:22

IL-36 gene expression in GPP lesions reduced by spesolimab

Presented By

Dr Ahmed Farag

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 15:09

Inhibition of heat shock protein: A novel way to treat psoriasis?

Presented By

Dr Anne Bregnhøj, Aarhus University Hospital, Denmark

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 15:02

Guselkumab shows highest drug survival among systemic treatments

Presented By

Dr Zenas Yiu, University of Manchester, UK

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 14:55

Risankizumab superior to ustekinumab in skin histopathology scores

Presented By

Dr Kathleen Smith

Trial

Phase 3, UltiMMa-1 trial

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 14:49

Tapering biologics: No alarming signs of increased anti-drug antibodies

Presented By

Dr Juul van den Reek , Radboudumc, the Netherlands

Trial

Phase 4, CONDOR

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 14:43

Intermediate monocytes are possible predictors of response to secukinumab

Presented By

Dr Jonathan Hardman-Smart, King’s College London, UK

Trial

Phase 3, SIGNATURE

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 14:34

Gut microbiota of psoriasis patients: less diverse and reduced functionality

Presented By

Dr Tanja Todberg, University of Copenhagen, Denmark

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 14:29

Psoriasis associated with a higher cancer risk

Presented By

Mr Alex Trafford, University of Manchester, UK

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 14:23

Comorbidity and clinical features of psoriasis vary according to HLA-C*06:02 status

Presented By

Dr Ravi Ramessur, King’s College London, UK

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 14:20

Psoriasis patients with cardiovascular comorbidity characterised by high systemic inflammation

Presented By

Dr Niamh Kearney, St. Vincent’s University Hospital, Ireland

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 14:16

HLA-C*06:02-positive patients on ustekinumab show higher drug survival in a real-world scenario

Presented By

Dr Oras Alabas, University of Manchester, UK

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 14:05

Selective IL-23 inhibition normalises gene expression in active PsA

Presented By

Ms Michelle Miron

Trial

Phase 3, DISCOVER-1&-2

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 13:48

Protective factors identified against anti-drug antibody formation to adalimumab in psoriasis

Presented By

Dr Teresa Tsakok, King’s College London, UK

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 13:37

PFGC 2021 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

PFGC 2021

22 December 2021 08:12

ICD 2021

An unusual case of E. coli cellulitis in an immunocompetent patient

Presented By

Ms Jacqueline Nguyen, St Vincent’s Hospital Melbourne Docklands, Australia

Conference

ICD 2021

Type

News article

2 December 2021 17:49

Autologous serum therapy benefits chronic spontaneous urticaria

Presented By

Dr Akash Agarwal, IMS and SUM Hospital Bhubaneswar, India

Conference

ICD 2021

Type

News article

2 December 2021 17:35

Age at disease onset: a key factor in understanding psoriasis

Type

News article

2 December 2021 17:26

Comparing routes of administration of methotrexate in psoriasis patients

Presented By

Mr Ishan Agrawal, Siksha O Anusandhan University Bhubaneswar, India

Conference

ICD 2021

Type

News article

2 December 2021 17:24

Expanding the toolbox: what is new in melanoma detection?

Presented By

Prof. James Grichnik, University of South Florida, USA

Conference

ICD 2021

Type

News article

2 December 2021 17:21

Equity in dermatology: Skin Care For All  

Presented By

Dr Jeslyn Tengkawan, Johns Hopkins University; Capella Project Foundation,

Conference

ICD 2021

Type

News article

2 December 2021 17:18

Challenges in diagnosis and treatment of leprosy in Brazil

Presented By

Prof. Caroline Talhari, Amazonas State University, Brazil

Conference

ICD 2021

Type

News article

2 December 2021 17:16

A PASSION to provide dermatological care in LMICs

Presented By

Dr Christophe Hsu, University Hospital of Basel, Switzerland

Conference

ICD 2021

Type

News article

2 December 2021 17:13

Paediatric dermatology in Tunisia: common diagnoses

Presented By

Dr Nejib Doss, Military Hospital of Tunis, Tunisia

Conference

ICD 2021

Type

News article

2 December 2021 17:08

Registry of vitiligo patients aims to break the stigma

Expert

Pirogov Russian National Research Medical University, Russia

Conference

ICD 2021

Type

News article

2 December 2021 17:02

Ceramides and their role in skincare

Presented By

Prof. John Su; Dr Katherine Armour

Conference

ICD 2021

Type

News article

2 December 2021 16:47

10% thioglycolic acid gel peels: a safe and efficient option for pigmented purpuric dermatosis

Presented By

Dr Arunima Ray, IMS and SUM Hospital, India

Conference

ICD 2021

Type

News article

2 December 2021 16:43

Benefits of microneedling with platelet-rich plasma for acne scars

Presented By

Dr Jaishree Sharad, Skinfiniti Aesthetic Skin and Laser Clinic, India

Conference

ICD 2021

Type

News article

2 December 2021 16:33

ICD 2021 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ICD 2021

29 November 2021 09:20

EADV 2021

Targeting OX40 in the treatment of atopic dermatitis meets expectations

Presented By

Prof. Stephan Weidinger, University Hospital Schleswig-Holstein, Germany

Trial

Phase 2

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:35

Superior EASI scores after switch from dupilumab to upadacitinib

Presented By

Prof. Andrew Blauvelt, Oregon Medical Research Center, USA

Trial

Heads Up

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:34

CSU: Novel agent targeting Bruton’s tyrosine kinase leads to disease control

Presented By

Prof. Marcus Maurer, Charité University Hospital, Germany

Trial

Phase 2

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:33

Novel JAK3/TEC blocker leads to maintained re-pigmentation in vitiligo

Presented By

Prof. Khaled Ezzedine, University Hospital Henri Mondor, France

Trial

Phase 2

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:32

TYK2 inhibitor deucravacitinib shows impressive long-term response in psoriasis

Presented By

Prof. Richard Warren, University of Manchester, UK

Trial

Phase 3, POETYK PSO

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:31

Letter from the Editor

Editor

Prof. Peter C.M. van de Kerkhof, Radboud University Medical Center, the Netherlands

Conference

EADV 2021

18 November 2021 13:30

Tapinarof cream for psoriasis leads to high clearance rates and remittive effect

Presented By

Dr Linda Stein Gold, Henry Ford Health System, USA

Trial

PSOARING 3

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:30

CSU: Ligelizumab likely safe and effective for adolescents

Presented By

Prof. Bülent Şekerel, Hacettepe University, Turkey

Trial

Phase 2

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:29

Long-term disease control in AD could be in reach with anti-OX40 antibody KHK4083

Presented By

Prof. Emma Guttman-Yassky, Icahn School of Medicine at Mount Sinai, USA

Trial

Phase 2

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:28

Topical JAK1/JAK2 inhibitor effective in vitiligo

Presented By

Dr David Rosmarin, Tufts Medical Center Boston, USA

Trial

Phase 3, TRuE-V1; TruE-V2

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:27

Abrocitinib demonstrates fast itch control and skin clearance in atopic dermatitis

Presented By

Prof. Kristian Reich, University Medical Center Hamburg-Eppendorf, Germany

Trial

Phase 3, JADE DARE

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:26

AD patients with stable response fare well with a monthly dose of tralokinumab

Presented By

Prof. Stephan Weidinger, University of Kiel, Germany

Trial

ECZTRA1 and 2

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:25

Damaged skin as a possible transmission route for SARS-CoV-2

Presented By

Dr Hanan Osman-Ponchet

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:24

Upadacitinib beats dupilumab in different body regions

Presented By

Prof. Jacob Thyssen, Bispebjerg Hospital, Denmark

Trial

Phase 3, Heads Up

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:23

Efficacious 2-year AD control with IL-13 inhibitor tralokinumab

Presented By

Prof. Andrew Blauvelt, Oregon Medical Research Center, USA

Trial

ECZTEND

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:22

Ruxolitinib cream: a safe treatment for elderly AD patients

Presented By

Prof. Jacek Szepietowksi, Wroclaw Medical University, Poland

Trial

Phase 3, TRuE-AD1; TRuE-AD2

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:21

Novel and upcoming targeted AD treatment

Presented By

Prof. Emma Guttman-Yassky, Icahn School of Medicine at Mount Sinai, USA

Trial

ECZTRA 3; Measure Up; ADVISE

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:20

Existing and upcoming small molecules in psoriasis

Presented By

Dr Enikö Sonkoly , Karolinska University Hospital, Sweden

Trial

POETYK PSO; PSOARING

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:19

Treating psoriasis during pregnancies

Presented By

Prof. Mahira Hamdy El Sayed, Ain Shams University, Egypt

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:18

A patient-related approach to freedom of disease

Presented By

Elfie Deprez , Ghent University Hospital, Belgium

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:17

Ixekizumab superior to secukinumab in real-world psoriasis study

Presented By

Dr Caterina Cariti, University of Turin, Italy

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:16

Nail psoriasis: An important target to be treated

Presented By

Prof. Peter van de Kerkhof , Radboudumc, the Netherlands

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:15

Grand debate: Is psoriasis a systemic or skin-only disease?

Presented By

Prof. Brian Kirby & Prof. Stefano Piaserico

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:14

JAK1/2: A promising novel treatment target in alopecia areata

Presented By

Prof. Brett King, Yale University School of Medicine, USA

Trial

Phase 3, BRAVE-AA1; BRAVE-AA2

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:12

Alopecia areata: encouraging response rates with JAK3/TEC inhibition

Presented By

Prof. Brett King, Yale University School of Medicine, USA

Trial

ALLEGRO

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:11

Opioid receptor agonist difelikefalin disappoints in AD

Presented By

Prof. Brian Kim, Washington University School of Medicine, USA

Trial

Phase 2, KARE

Conference

EADV 2021

Type

Peer-reviewed article

17 November 2021 14:28

EADV 2021 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Trial

PSOARING 3, JADE-DARE, HEADS UP

Conference

EADV 2021

19 October 2021 00:08

AAD 2021

Allergies: an underrated factor in alopecia pathogenesis

Presented By

Prof. Natasha Mesinkovska, UC Irvine School of Medicine, CA, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:45

Psoriasis and hidradenitis suppurativa during COVID-19: keep calm and carry on

Presented By

Prof. April W. Armstrong, University of Southern California, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:32

Psoriasis: The treatment armamentarium continues to grow

Presented By

Prof. Bruce Strober, Yale University, CT, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:32

COVID-19 in children – cutaneous involvement is common

Presented By

Prof. Elena B. Hawryluk, Massachusetts General Hospital, MA, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:31

Psoriasis management in times of COVID-19: the knowledge is growing steadily

Presented By

Prof. Joel Gelfand, University of Pennsylvania Perelman School of Medicine, PA, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:31

Cutaneous reactions after COVID-19 vaccination: an update

Presented By

Prof. Esther Freeman, Harvard Medical School, MA, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:30

Sunless tanning and other developments in sun protection

Presented By

Dr Henry Lim, Henry Ford Health System, MI, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:30

Comorbidity does not influence crisaborole efficacy in atopic dermatitis

Trial

Phase 3, CrisADe CORE 1 and 2

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:30

Comorbidity is common in adult and paediatric atopic dermatitis patients

Presented By

Prof. Jonathan Silverberg, George Washington University, WA, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:30

Lower burden of high-risk atherosclerotic plaques in psoriasis patients treated with biologics

Presented By

Prof. Nehal N. Mehta, National Heart, Lung, and Blood Institute, MD, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:30

Botulinum toxin A: a contradictory role in hair loss

Presented By

Prof. Natasha Mesinkovska, UC Irvine School of Medicine, CA, USA

Conference

aad vmx 2021

Type

Peer-reviewed article

7 June 2021 13:21

New therapeutic options add value to current acne treatment

Presented By

Dr John Barbieri, Perelman School of Medicine, University of Pennsylvania, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:20

Significant improvements in the system armamentarium for AD treatment

Presented By

Prof. Eric Simpson, Oregon Health & Science University, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:20

Nicotinamide and probiotics can support acne therapy

Presented By

Prof. Juliana Choi, Penn Dermatology Perlman, PA, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:15

Convincingly low levels of infections with long-term tildrakizumab

Trial

reSURFACE 1 and 2

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:15

No increased risk of infection with long-term dupilumab for atopic dermatitis

Trial

LIBERTY AD OLE

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:15

Topical pan-JAK inhibitor cream safe and efficacious in atopic dermatitis

Presented By

Prof. Jonathan Silverberg, George Washington University, WA, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:10

Atopic dermatitis in children has a severe impact on their families

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:05

IL-17 inhibitor effective in axial manifestations of psoriatic arthritis

Trial

Phase 3, MAXIMISE

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:00

Platelet-rich plasma in androgenetic alopecia – hype or hope?

Presented By

Prof. Ronda S. Farah, University of Minnesota, MN, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:00

‘Maskne’ – How can it be managed?

Presented By

Prof. Juliana Choi, Penn Dermatology Perlman, PA, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:00

Meaningful amelioration of quality of life in paediatric AD patients on dupilumab

Trial

Phase 3, LIBERTY AD PEDS

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:00

Small molecule effective in moderate-to-severe psoriasis

Presented By

Prof. April Armstrong, Keck School of Medicine at UCLA, CA, USA

Trial

Phase 3, POETYK PSO-1 and 2

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 10:50

Bruton’s tyrosine kinase inhibition promising for pemphigus vulgaris

Presented By

Prof. Dedee F. Murrell, St George Hospital, University of New South Wales, Australia

Trial

Phase 2, BELIEVE

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 10:48

Bimekizumab superior to secukinumab in psoriasis

Presented By

Prof. Kristian Reich, University Medical Center Hamburg-Eppendorf, Germany

Trial

Phase 3, BE RADIANT

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 10:47

Etrasimod – a new mode of action for treatment of atopic dermatitis

Presented By

Prof. Emma Guttman-Yassky, Icahn School of Medicine at Mount Sinai, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 10:45

Women at higher risk for dermatologic side effects during immunotherapy

Presented By

Mr Jordan T. Said, Harvard School of Medicine, MA, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 10:44

Novel easy-to-use foam formulation clears scalp psoriasis in one-third of patients

Presented By

Prof. Leon Kircik, Icahn School of Medicine at Mount Sinai Medical Center, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 10:43

Anti-cholinergic gel demonstrates superior long-term tolerability and efficacy in axillary hyperhidrosis

Presented By

Dr Brandon M. Kirsch, Kirsch Dermatology, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 10:42

Letter from the Editor

Editor

Prof. Peter C.M. van de Kerkhof, Radboud University Medical Center, the Netherlands

Conference

AAD VMX 2021

3 June 2021 16:03

AAD VMX 2021 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

AAD VMX 2021

11 May 2021 15:01